科创生物医药ETF(588250)早盘涨0.57%,创新药审批提速提振成分股

Group 1 - The core viewpoint of the news highlights the positive market reaction to the approval of 11 innovative drugs by the National Medical Products Administration, leading to a rise in the related stocks of innovative pharmaceutical companies [1] - The Science and Technology Conference on June 24 emphasized the focus on biotechnology and technological innovation, providing long-term support for the biopharmaceutical industry [2] - The research from securities firms indicates that the internationalization of Chinese innovative drugs is progressing, with significant representation at the 2025 ASCO conference and record upfront payments for licensing agreements, showcasing the global competitiveness of companies like Zai Lab [2] Group 2 - The performance of the ChiNext Biopharmaceutical ETF (588250.SH) and its constituent stocks, such as EdiGene and Zai Lab, reflects a strong market sentiment towards innovative drug approvals [1] - The major constituent stocks of the ETF, including EdiGene, Zai Lab, and others, have shown significant price increases, indicating investor confidence in the sector [1] - The list of associated products and stocks includes various innovative pharmaceutical companies, highlighting the breadth of the sector's representation [3]